DASH vs RIGL · P/E 76, rev $13.72B vs P/E 9.1, rev $179.3M
DoorDash, Inc. Class A Common Stock (DASH) versus Rigel Pharmaceuticals Inc (RIGL) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Not investment advice. Open the DASH and RIGL stock pages for the full models.
Not investment advice.